Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. received an amended Schedule 13G showing that Daniel Antonio Perez beneficially owns 10,373,350 shares of Class A common stock on an as-converted basis, representing 15.7% of the class.
This percentage is based on 55,883,690 Class A shares outstanding as of December 31, 2025. The position includes 9,822,175 Class A shares underlying Class B shares held by Perez, 515,705 Class A shares underlying Class B shares held by his spouse, and 35,470 Class A shares held directly by his spouse. Perez has sole voting and dispositive power over 9,822,175 shares and shared power over 551,175 shares.
Alkeon Capital Management LLC and Panayotis D. Sparaggis have filed an amended Schedule 13G reporting beneficial ownership in Hinge Health, Inc. Class A common stock. They report holding 791,104 shares, representing 2.1% of the Class A shares outstanding.
The ownership percentages are based on 37,919,155 Class A shares outstanding as of October 30, 2025, as disclosed in Hinge Health’s Form 10-Q for the quarter ended September 30, 2025. Both reporting persons list shared voting and dispositive power over the same 791,104 shares and no sole power.
The filing date of the signatures is February 13, 2026, with an event date triggering the filing of December 31, 2025. The filing confirms that the reporting persons’ holdings are 5 percent or less of Hinge Health’s Class A common stock.
Hinge Health, Inc. received an amended Schedule 13G from a group of Insight-managed investment entities reporting significant ownership of its Class A Common Stock. The Insight entities collectively beneficially own 9,375,164 shares of Class B Common Stock, which are exchangeable into an equal number of Class A shares on a one-for-one basis.
For percentage calculations, these Class B shares are treated as converted into Class A, giving the Reporting Persons beneficial ownership of approximately 19.8% of the 47,294,319 shares of Class A Common Stock deemed outstanding. If all outstanding Class B shares reported in the company’s Form 10-Q were similarly converted, the Insight entities would be deemed to beneficially own approximately 11.9% of the Class A Common Stock. The filing is made jointly by several Insight funds and related general partner and holding entities, which may be deemed to form a group for reporting purposes, though they expressly disclaim group status beyond this joint filing.
Hinge Health, Inc. CEO, Co-Founder, director and 10% owner Daniel Antonio Perez reported a planned share sale. On February 12, 2026, he converted 166,665 shares of Class B Common Stock into the same number of Class A shares at $0 per share, then sold 166,665 Class A shares in open-market transactions at a weighted average price of $40.2635, under a Rule 10b5-1 trading plan adopted on September 11, 2025. Following these transactions, his directly held Class A position reported in this filing is 0 shares, while he directly holds 9,488,845 Class B shares and has additional indirect holdings through his spouse.
Hinge Health, Inc. received an amended Schedule 13G showing that investment entities affiliated with 11.2 Capital and individual filer Qian Zhuang collectively beneficially own 3,704,524 shares of the company’s Class A common stock. This represents 9.8% of the class, based on 37,919,155 shares outstanding as of October 30, 2025.
The ownership is held through several Delaware entities: 11.2 Capital I, L.P. with 2,703,954 shares, 11.2 Capital HH, LLC with 171,550 shares, and 11.2 Capital IVY, LLC with 829,020 shares. The filing notes that the reporting persons share voting and dispositive power over these shares and expressly disclaim status as a group. Zhuang is identified as the sole managing member of the general partner and manager entities that control these holdings.
Bessemer Venture Partners entities filed a notice to sell 242,100 Class A shares through Merrill Lynch on the NYSE, with an aggregate market value of 9,383,796 and 37,919,155 Class A shares outstanding. The approximate sale date is 02/12/2026.
The shares to be sold were acquired on 02/04/2020 in a private placement from the issuer for cash. The filing also lists recent Class A share sales over the past three months by Bessemer Venture Partners X LP and Bessemer Venture Partners X Institutional LP, including multiple transactions in November and December 2025 with disclosed gross proceeds.
A holder of HNGE Class A shares has filed a Rule 144 notice to sell 257,900 Class A shares through Merrill Lynch on the NYSE, with an aggregate market value of $9,996,204. The notice states that 37,919,155 Class A shares were outstanding when the filing was prepared.
The shares to be sold were originally acquired on February 4, 2020 in a private placement from the issuer, paid for in cash. The filing also lists recent sales, including Bessemer Venture Partners X LP selling 373,955 Class A shares on November 18, 2025 for $14,976,898, and Bessemer Venture Partners X Institutional LP selling 351,045 Class A shares the same day for $14,059,352.
HNGE insider Daniel Perez has filed a Rule 144 notice to sell 166,665 common shares through Morgan Stanley Smith Barney LLC. The planned sale has an aggregate market value of $6,459,935.40 and is scheduled for approximately 02/12/2026 on the NYSE.
The shares to be sold were acquired as restricted stock awards from the issuer on 08/25/2020. The form also notes that 37,919,155 common shares are outstanding. Perez is relying on a Rule 10b5-1 trading plan, with recent plan-related sales over the past three months.
Hinge Health, Inc. reported record fourth quarter and full-year 2025 results with rapid growth and improving profitability. Revenue rose 46% year over year in Q4 to $170.7 million, and 51% for 2025 to $587.9 million, as more employers and members adopted its digital musculoskeletal programs.
GAAP income from operations in Q4 increased to $27.3 million with an 84% gross margin, while non-GAAP income from operations reached $48.0 million. For 2025, non-GAAP income from operations was $119.5 million versus a loss in 2024, but GAAP loss from operations widened to $546.4 million largely due to $643.0 million of stock-based compensation.
Operating cash flow for 2025 grew to $171.4 million and free cash flow to $179.6 million, with cash, cash equivalents, marketable securities and restricted cash of $478.8 million at year-end. The company also repurchased $65.0 million of Class A common stock under a $250.0 million authorization and guided 2026 revenue to $732–$742 million with higher non-GAAP operating margins.
Hinge Health, Inc. president James Pursley reported an exempt tax-withholding transaction involving company stock. On 02/01/2026, 1,429 shares of Class A Common Stock were withheld at $34.90 per share to cover federal and state tax obligations from vesting restricted stock units.
These shares were relinquished by Pursley and cancelled by Hinge Health in exchange for the company paying his related tax liabilities. After this administrative transaction, he beneficially owned 767,231 shares of Class A Common Stock directly.
FAQ
What is the current stock price of Hinge Health (HNGE)?
What is the market cap of Hinge Health (HNGE)?
